Journal ArticleDOI
HMG CoA reductase inhibitors and the risk of colorectal cancer
Jenny N. Poynter,Gadi Rennert,Joseph D Bonner,Hedy S. Rennert,Joel K. Greenson,Stephen B. Gruber +5 more
Reads0
Chats0
TLDR
HMG CoA reductase inhibitors are associated with a 51% reduction in the risk of colorectal cancer, and the protective effect is specific to this class of lipid-lowering agents.Abstract:
1 Background: 3-hydroxy-2-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors are effective lipid-lowering agents that also inhibit the growth of colon cancer cell lines and were noted to be a...read more
Citations
More filters
Journal ArticleDOI
P53 as a prognostic marker for bladder cancer: a meta-analysis and review
Núria Malats,Aurelia Bustos,Cristiane M Nascimento,Francisco J. Martín Fernández,M. Rivas,Diana Puente,Manolis Kogevinas,Francisco X. Real +7 more
TL;DR: Evidence is not sufficient to conclude whether changes in P53 act as markers of outcome in patients with bladder cancer, and the methods used to assess significance varied widely between studies.
Journal ArticleDOI
Statins Reduce the Risk of Lung Cancer in Humans: A Large Case-Control Study of US Veterans
TL;DR: Statins appear to be protective against the development of lung cancer, and further studies need to be done to define the clinical utility of statins as chemo protective agents.
Journal ArticleDOI
Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
Marc-Eric Halatsch,Ursula Schmidt,Julianne Behnke-Mursch,Andreas Unterberg,Christian Rainer Wirtz +4 more
TL;DR: The HER1/EGFR tyrosine kinase inhibitors erlotinib and gefitinib are in advanced clinical development for glioma, and a number of trials are in progress, or have recently been completed.
Journal ArticleDOI
Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]
Granada Perea,Adriana Lasa,Anna Aventin,Alicia Domingo,Neus Villamor,M. Paz Queipo De Llano,Andreu Llorente,Jordi Juncà,C. Palacios,C. Fernández,M. Gallart,Llorens Font,Mar Tormo,Lourdes Florensa,J. Bargay,Josep Martí,Pilar Vivancos,Pio Torres,Juan Berlanga,Isabel Badell,Salut Brunet,Jordi Sierra,Josep F. Nomdedeu +22 more
TL;DR: Combined use of FC and RQ-PCR may improve MRD detection, and provide useful clinical information on relapse kinetics in AML patients.
Journal ArticleDOI
Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
Malisetty V. Swamy,Jagan M.R. Patlolla,Vernon E. Steele,Levy Kopelovich,Bandaru S. Reddy,Chinthalapally V. Rao +5 more
TL;DR: Observations show that atorvastatin inhibits intestinal tumorigenesis and that, importantly, when given together with low doses of celecoxib, it significantly increases the chemopreventive efficacy in an APC(min) mice.